What evidence did the MRC-BHF Heart Protection Study provide in 2002?
The MRC-BHF Heart Protection Study provided evidence in 2002 that cholesterol lowering with simvastatin in 20,536 high-risk individuals could be beneficial in terms of preventing cardiovascular events and death. This was a randomised, placebo-controlled trial that showed that simvastatin treatment significantly reduced the risk of major coronary events, non-fatal myocardial infarction and stroke, as well as all-cause mortality. The study concluded that simvastatin was a safe and effective treatment for individuals at high risk of cardiovascular events.